Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q3 2025 Earnings Presentation
17 slides from Bactiguard Holding Ab's earnings presentation, Oct 23, 2025
Slide 1: Q3 2025 presentation
Q3 2025 presentation Thursday 23 October 2025 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Q3 2025 key figures and highlights
Q3 2025 key figures and highlights Continued profitability and clinical evidence supporting future growth Key figures for Q3 2025 (Q3 2024) Highlights • License revenue from BD bounce back, Revenues 48.4 (73.9) MSEK Zimmer Biomet limited as expected • Continue to add to clinical evidence EBITDA 5.3
Slide 3: Setting the standard of care in infection prevention
Setting the standard of care in infection prevention Unmet medical need Validated technology Healthcare-associated infections and chronic Products on market with global MedTech wounds create a multi-billion cost burden partners, supported by clinical evidence Scalable platform Growth drivers Leverag
Slide 4: Advanced technology to prevent medical device related infections
Advanced technology to prevent medical device related infections Reduces microbial adhesion and biofilm formation • Ultra-thin noble metal coating • In contact with fluids, the noble metals create a galvanic effect due to their varying electro potentials 20+ 250M+ materials coated devices coated 100
Slide 5: Our strategic focus therapeutic areas
Our strategic focus therapeutic areas Focus therapeutic areas Orthopedics1-3 Cardiology 4,5 Neurology 6,7 Urology 8 Vascular access 9 Hip & Knee Implants Deep Brain Stimulator Central Venous Catheter Application areas Ventricular Assisted Device Foley Catheter Spinal discs / Fusion cages Vagus Nerve
Slide 6: Partnership snapshot Q3 2025
Partnership snapshot Q3 2025 Exclusivity partnerships and License partnerships announced with partner name Material transfer Application development Exclusivity partnership License partnership agreement partnership Orthopedics Cardiology Neurology Urology Vascular access Other 6
Slide 7: BD partnership update
BD partnership update Strong momentum in partnership • Collaboration spanning entire value chain – from technology licensing to go-to-market strategies • Dedicated Bactiguard-coated Foley catheters US website with evidence-based insights on clinical and economic benefits • Active market transition i
Slide 8: Zimmer Biomet partnership update
Zimmer Biomet partnership update Commercialization of ZNN Bactiguard across Europe continues • ZNN Bactiguard part of Zimmer Biomet Infection strategic pillar within prevention solutions • Commercialization of ZNN Bactiguard across Europe – European Bone & Joint Infection Society (Barcelona, Septemb
Slide 9: Adding to clinical evidence on Bactiguard-coated implants
Adding to clinical evidence on Bactiguard-coated implants Orthopedic trauma nail Two independent clinical studies published in medical journals strengthen the evidence base for Bactiguard’s coated implants UK-based pilot study (Leeds Major Trauma Centre, Leeds, UK) Compares Bactiguard-coated vs. ant
Slide 10: Wound Management by Bactiguard
Wound Management by Bactiguard Preventing infections through effective, biocompatible solutions to improve wound healing • Continued growth of Hydrocyn aqua across all regions – while we see decline in sutures • YTD Wound Management revenues grew 8% – WM still expected to deliver double-digit growth
Slide 11: Total revenue decreased to SEK 48m in Q3 against high comparisons LY
Total revenue decreased to SEK 48m in Q3 against high comparisons LY as well as currency headwind Revenue development MSEK Other revenues BIP portfolio Wound Management portfolio Total license revenue Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 261,9 20,2 231,5 -15,7% 16,0 15,6 193,
Slide 12: Total license revenues decreased to SEK 30m in Q3 despite positive BD bounce back
Total license revenues decreased to SEK 30m in Q3 despite positive BD bounce back License revenue development MSEK Application development partners Exclusivity partners License partners Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 164,7 7,7 1,5 147,5 -14,4% 2,5 0,7 120,5 5,3 1,0 103,
Slide 13: Total operating costs (OPEX) further decreased in Q3 with YTD savings of 22%
Total operating costs (OPEX) further decreased in Q3 with YTD savings of 22% Total operating costs (OPEX) development MSEK Personnel costs Other external expenses Other operating expenses Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 207,9 -22,0% 174,3 153,6 111,5 119,8 100,9 81,5 -35
Slide 14: Continued positive EBITDA of SEK 5.3m in Q3 and SEK 19m in YTD
Continued positive EBITDA of SEK 5.3m in Q3 and SEK 19m in YTD EBITDA development MSEK EBITDA Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 27.5 +9.5 19.1 18.0 -4.6 9.9 9.6 5.3 2024 2025 2024 2025 2024 2024/25 14 Source: Bactiguard Holding AB, Interim report Q3 2025, p. 14
Slide 15: Cash flow from operations for Q3 at SEK –2.8m and total cash position
Cash flow from operations for Q3 at SEK –2.8m and total cash position end of Q3 of SEK 37.4m Cash flow for the period and total cash development MSEK 46,1 -2,8 -2,5 -3,1 -0,3 37,4 Cash end Cash flow Cash flow Cash flow Exchange Cash end of Q2 2025 from operating from investing from financing differe
Slide 16: Committed to deliver on our 2030 targets
Committed to deliver on our 2030 targets Strategic focus Targets by year-end 2030 application areas License partnerships Advance current and develop new partnerships >10 in either exclusivity or license partnership R&D Medical Continue to invest in key >200 MSEK EBITDA knowledge areas Regulatory Wo
Slide 17: Questions & Answers
Questions & Answers Q3 2025 presentation Christine Lind Patrick Bach CEO CFO